203 related articles for article (PubMed ID: 34985725)
41. Genetic polymorphisms of enzyme proteins and transporters related to methotrexate response and pharmacokinetics in a Japanese population.
Hashiguchi M; Shimizu M; Hakamata J; Tsuru T; Tanaka T; Suzaki M; Miyawaki K; Chiyoda T; Takeuchi O; Hiratsuka J; Irie S; Maruyama J; Mochizuki M
J Pharm Health Care Sci; 2016; 2():35. PubMed ID: 27980801
[TBL] [Abstract][Full Text] [Related]
42. Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis.
Wang X; Song Y; Wang J; He J; Liu R; Li X; Huang H; Zhang J
Int J Clin Pharm; 2020 Feb; 42(1):23-30. PubMed ID: 31916121
[TBL] [Abstract][Full Text] [Related]
43. Evaluation and Application of Population Pharmacokinetic Models for Identifying Delayed Methotrexate Elimination in Patients With Primary Central Nervous System Lymphoma.
Mao J; Li Q; Li P; Qin W; Chen B; Zhong M
Front Pharmacol; 2022; 13():817673. PubMed ID: 35355729
[No Abstract] [Full Text] [Related]
44. Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma.
Hegyi M; Arany A; Semsei AF; Csordas K; Eipel O; Gezsi A; Kutszegi N; Csoka M; Muller J; Erdelyi DJ; Antal P; Szalai C; Kovacs GT
Oncotarget; 2017 Feb; 8(6):9388-9398. PubMed ID: 27566582
[TBL] [Abstract][Full Text] [Related]
45. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.
Narumi K; Sato Y; Kobayashi M; Furugen A; Kasashi K; Yamada T; Teshima T; Iseki K
Biopharm Drug Dispos; 2017 Dec; 38(9):501-508. PubMed ID: 28801980
[TBL] [Abstract][Full Text] [Related]
46. A minimal physiologically based pharmacokinetic model for high-dose methotrexate.
Pesenti G; Foppoli M; Manca D
Cancer Chemother Pharmacol; 2021 Oct; 88(4):595-606. PubMed ID: 34120234
[TBL] [Abstract][Full Text] [Related]
47. Vancomycin: a review of population pharmacokinetic analyses.
Marsot A; Boulamery A; Bruguerolle B; Simon N
Clin Pharmacokinet; 2012 Jan; 51(1):1-13. PubMed ID: 22149255
[TBL] [Abstract][Full Text] [Related]
48. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
49. MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase.
Taylor ZL; Mizuno T; Punt NC; Baskaran B; Navarro Sainz A; Shuman W; Felicelli N; Vinks AA; Heldrup J; Ramsey LB
Clin Pharmacol Ther; 2020 Sep; 108(3):635-643. PubMed ID: 32558929
[TBL] [Abstract][Full Text] [Related]
50. Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate.
Choi YJ; Park H; Lee JS; Lee JY; Kim S; Kim TW; Park JS; Kim JE; Yoon DH; Suh C
Hematol Oncol; 2017 Dec; 35(4):504-509. PubMed ID: 27781293
[TBL] [Abstract][Full Text] [Related]
51. Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.
Lemaitre F; Bezian E; Goldwirt L; Fernandez C; Farinotti R; Varnous S; Urien S; Antignac M
Ther Drug Monit; 2012 Dec; 34(6):686-94. PubMed ID: 23131698
[TBL] [Abstract][Full Text] [Related]
52. Toward pharmacogenetic SLCO1B1-guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model.
Taylor ZL; Thompson LE; Bear H; Mizuno T; Vinks AA; Ramsey LB
Clin Transl Sci; 2021 Nov; 14(6):2267-2277. PubMed ID: 34121338
[TBL] [Abstract][Full Text] [Related]
53. The effect of malignant effusions on methotrexate disposition.
Li J; Gwilt P
Cancer Chemother Pharmacol; 2002 Nov; 50(5):373-82. PubMed ID: 12439595
[TBL] [Abstract][Full Text] [Related]
54. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
[TBL] [Abstract][Full Text] [Related]
55. Pharmacogenomics of Methotrexate: Current Status and Future Outlook.
Cao M; Guo M; Wu DQ; Meng L
Curr Drug Metab; 2018; 19(14):1182-1187. PubMed ID: 29283070
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of possible pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats.
Ueda H; Narumi K; Sato Y; Furugen A; Kobayashi M; Iseki K
Pharmacol Rep; 2020 Oct; 72(5):1426-1432. PubMed ID: 32671657
[TBL] [Abstract][Full Text] [Related]
57. Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients.
Yukawa E; Mori S; Ueda K; Nakada Y
J Clin Pharm Ther; 2007 Dec; 32(6):573-8. PubMed ID: 18021334
[TBL] [Abstract][Full Text] [Related]
58. Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy.
Simon N; Marsot A; Villard E; Choquet S; Khe HX; Zahr N; Lechat P; Leblond V; Hulot JS
Pharmacogenomics J; 2013 Dec; 13(6):507-13. PubMed ID: 23069858
[TBL] [Abstract][Full Text] [Related]
59.
Roszkiewicz J; Michałek D; Ryk A; Swacha Z; Szmyd B; Smolewska E
Scand J Rheumatol; 2021 May; 50(3):213-217. PubMed ID: 33025831
[No Abstract] [Full Text] [Related]
60. Endogenous metabolites that are substrates of organic anion transporter's (OATs) predict methotrexate clearance.
Muhrez K; Benz-de Bretagne I; Nadal-Desbarats L; Blasco H; Gyan E; Choquet S; Montigny F; Emond P; Barin-Le Guellec C
Pharmacol Res; 2017 Apr; 118():121-132. PubMed ID: 27210722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
